Table 3.
Best overall response in patients receiving BI 836826 plus GemOx
| BI 836826 dose | ||||
|---|---|---|---|---|
| Patients with response, n (%) | 25 mg (n = 5) |
50 mg (n = 8) |
100 mg (n = 8) |
Total (n = 21) |
| Complete remission | 1 (20.0) | 0 | 1 (12.5) | 2 (9.5) |
| Partial remission | 2 (40.0) | 3 (37.5) | 1 (12.5) | 6 (28.6) |
| Stable disease | 2 (40.0) | 1 (12.5) | 3 (37.5) | 6 (28.6) |
| Progressive disease | 0 | 2 (25.0) | 1 (12.5) | 3 (14.3) |
| Missing | 0 | 2 (25.0) | 2 (25.0) | 4 (19.0) |
GemOx gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2